‎Singapore: US based biosimilar therapeutic developer, Coherus BioSciences, has started its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar for rheumatoid arthritis (RA).

The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active RA who have demonstrated an inadequate response to methotrexate..

"The initiation of a CHS-0214 Phase 3 study is an important event for RA patients," said Dr Barbara Finck, chief medical officer, Coherus. "This trial of biosimilar etanercept advances our goal to expand access to this life-changing medication for patients with RA."

"This trial marks our transition to a Phase 3 company," said Mr Denny Lanfear, chief executive officer, Coherus. "In concert with our partners, Daiichi Sankyo and Baxter, we are pleased to advance this product to the final stage of development."